Table 4.

Dose modifications (all evaluable patients, n = 37)

EventNumber (%)
Any dose modification (interruption, reduction, or discontinuation)21 (57%)
Treatment interruption9 (24%)
Dose reductions19 (51%)
Discontinuation due to toxicity1 (3%), fatigue
Reasons for dose modification
 Neutropenia
  Overall17 (46%)
  Grade 316 (43%)
  Grade 41 (3%)
 Thrombocytopenia
  Overall3 (8%)
  Grade 32 (5%)
  Grade 41 (3%)
 Final dose
  125 mg18 (49%)
  100 mg12 (32%)
  75 mg6 (16%)
  50 mg1 (3%)